A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of
experimental drug CS5001 in patients with advanced hematological and solid tumors.